Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- ActHIB Recalled due to Contamination
March 21, 2011
- Nihon Medi-Physics Provides Radiocesium Decontaminating Agent Free of Charge
March 21, 2011
- Applications Expected for Inactivated Polio Vaccines at End of 2011
March 21, 2011
- Memantine, Galantamine Enter NHI Price List
March 14, 2011
- EC to Maintain Approval of Avastin + Paclitaxel for Metastatic Breast Cancer
March 14, 2011
- New Task Force to Be Created for Reform of Pharmaceutical Regulations
March 14, 2011
- Restriction on Use of Multiple Drugs in the Elderly Needs Careful Review: Dr Adachi
March 14, 2011
- JPMA Introduces GL for Disclosure of Funds Provided to Healthcare Professionals
March 14, 2011
- Terumo to Launch DuraHeart in April
March 14, 2011
- Zyprexa Applied for Depressive Symptoms Associated with Bipolar Disorders
March 14, 2011
- Terumo's Drug-eluting Stent Recommended for Approval
March 14, 2011
- 14-Day Prescription Limit Will Not Apply to Sonias
March 14, 2011
- 4 Deaths Reported Following Simultaneous Vaccination with Prevnar, ActHIB, DPT Vaccine
March 14, 2011
- Banzel Oral Suspension Approved in the US: Eisai
March 14, 2011
- Tumor Lysis Syndrome Added as Serious ADR Associated with Imatinib, Nilotinib
March 14, 2011
- Eisai to Shift Priority to East Asia
March 14, 2011
- Daiichi Sankyo to Acquire Plexxikon
March 14, 2011
- Bayer Aims to Launch Rivaroxaban in 2012 in Japan
March 14, 2011
- Ajinomoto Aims at Pharma Sales of ¥87.4 Bil. in FY2013
March 14, 2011
- Drastic Reform Necessary to Strengthen Japan's Competitiveness: Mr Mitani of Novartis
March 14, 2011
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…